GSK fights patent office again

Once again, GlaxoSmithKline is charging into patent court on Big Pharma's behalf. The drugmaker is playing point against some procedural changes the U.S. Patent and Trademark Office proposed last year; GSK already got a district judge to throw out the rules, but now the issue is up for appeal.

Designed to clear up a backlog at the patent office--a whopping 700,000-application backlog, in fact--the rules would reduce the number of ways patents can be defined and cut the number of times they can be amended. GSK and other drugmakers say the rules would erode their ability to protect their discoveries, and thus would discourage innovation. Other companies have weighed in on the same side, including agricultural giant Monsanto and General Electric.

If GSK prevails once again, Congress would have to intervene to make the changes the PTO wants.

- read the WSJ Health Blog item

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.